NOVEL CORONAVIRUS DISEASE (COVID-19) –DETECTION, TREATMENT AND EFFECT ON GLOBAL ECONOMY

PDF

Published: 2020-07-30

Page: 35-41


JYOTI SARWAN

Chandigarh University, Mohali, India and University Institute of Pharmacy, India.

HEENU SHARMA

Chandigarh University, Mohali, India and University Institute of Pharmacy, India.

J. C. BOSE

Chandigarh University, Mohali, India and University Institute of Pharmacy, India.

*Author to whom correspondence should be addressed.


Abstract

COVID-19 a viral pandemic caused by novel coronavirus COVID19 which was the modified form of SARS CoV-2 and MERS CoV-2 was first found in Wuhan, China but nowadays it had spread all over the world. More than 213 Countries and Territories around the world have affected by the coronavirus COVID-19 and many more nations have been going through most critical situations in health and financial contexts as well. So many major attempts are made practicing to overcome negative impacts of this viral infection but there is no permanent solution has not been found yet. No availability of either vaccine or therapeutic antiviral drugs till now in any country to prevent and cure this infection. As the COVID19 infections were asymptomatic, the proper serodiagnostic tools also very essential besides the real time PCR as it takes much time for the results. Some of the practices have been running continuously like detection methods and alternative treatments for this major virus respiratory infection. But the major issue to be resolved patients are found be in again re-infection by COVID19.

Keywords: COVID-19, pandemic, coronavirus, SARS CoV-2, global economy.


How to Cite

SARWAN, J., SHARMA, H., & BOSE, J. C. (2020). NOVEL CORONAVIRUS DISEASE (COVID-19) –DETECTION, TREATMENT AND EFFECT ON GLOBAL ECONOMY. PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY, 21(19-20), 35–41. Retrieved from https://ikprress.org/index.php/PCBMB/article/view/5238

Downloads

Download data is not yet available.

References

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China; 2019.

Anna Petherick, Developing antibody tests for SARS-CoV-2. 2020;395.

Cascella Marco, et al. Features, evaluation and treatment coronavirus (COVID-19). Statpearls [internet]. Stat Pearls Publishing; 2020.

Guo Yan-Rong, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status." Military Medical Research 7.1. 2020;1-10.

Jakson JK, Weiss MA, Schawarzenberg AB. Global economy effect on COVID-19, Congression Research Services. 2020; R46270.

Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, Peng L. Recurrence of positive SARS CoV-2 in RNA fragments. International Journal of Infectious Diseases. 2020;93: 297-299.

Zhang F, Abudayyeh OO, Gootenberg SJ. A protocol for detection of COVID-19 by using CRISPR. Nature Protocol. 2020;10: 2986-3012.

Smith TDP, Prosser T. COVID-19 drug therapy- potential option. Elesveir. 2020; 26.

Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon Alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. J Am Med Assoc. 2003; 290(24):3222–3228.

Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003;361(9371):1767– 1772.

Jin Y, Cai L, Cheng Z, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 2020;7:4.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet; 2020.

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30:269–271.

Tian S, Hu W, Niu L, Liu H, Xu H, Yuan X. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer- FEB. International Association for the Study of Lung Cancer. 2020;10:1550-0864.

Gautret P, Lageir JC, Parola P, Thuan V, Line H, Maille. M, Doudier B, Viera E, Didier R. Hydroxychloroquine and azithromycin as a treatment of COVID-19 results of open clinical trials. International Journals of Antimicrobial Agents. 2020; 105494